New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
07:06 EDTMYGNMyriad Genetics Prolaris test predicts risk of prostate cancer recurrence
Myriad Genetics announced that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
16:28 EDTMYGNMyriad Genetics board approves $200M increase in share buyback program
Subscribe for More Information
February 17, 2015
10:53 EDTMYGNScopia Capital reports 5.87% passive stake in Myriad Genetics

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use